MX2021009488A - Uso de vibegron para tratar la vejiga hiperactiva. - Google Patents

Uso de vibegron para tratar la vejiga hiperactiva.

Info

Publication number
MX2021009488A
MX2021009488A MX2021009488A MX2021009488A MX2021009488A MX 2021009488 A MX2021009488 A MX 2021009488A MX 2021009488 A MX2021009488 A MX 2021009488A MX 2021009488 A MX2021009488 A MX 2021009488A MX 2021009488 A MX2021009488 A MX 2021009488A
Authority
MX
Mexico
Prior art keywords
vibegron
overactive bladder
treat overactive
treat
subject
Prior art date
Application number
MX2021009488A
Other languages
English (en)
Spanish (es)
Inventor
Jr Paul N Mudd
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of MX2021009488A publication Critical patent/MX2021009488A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021009488A 2019-03-18 2020-03-18 Uso de vibegron para tratar la vejiga hiperactiva. MX2021009488A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US201962904429P 2019-09-23 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
MX2021009488A true MX2021009488A (es) 2021-09-21

Family

ID=70166082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009488A MX2021009488A (es) 2019-03-18 2020-03-18 Uso de vibegron para tratar la vejiga hiperactiva.

Country Status (14)

Country Link
US (1) US20230027066A1 (cg-RX-API-DMAC7.html)
EP (2) EP4763281A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022524576A (cg-RX-API-DMAC7.html)
KR (2) KR20260049872A (cg-RX-API-DMAC7.html)
CN (2) CN121489955A (cg-RX-API-DMAC7.html)
AU (2) AU2020243514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129024A1 (cg-RX-API-DMAC7.html)
IL (1) IL285910A (cg-RX-API-DMAC7.html)
MX (1) MX2021009488A (cg-RX-API-DMAC7.html)
PH (1) PH12021551975A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108810YA (cg-RX-API-DMAC7.html)
TW (2) TW202506129A (cg-RX-API-DMAC7.html)
WO (1) WO2020188505A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆(vibegron)於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍(vibegron)治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Kcnq2〜5チャネル関連疾患の予防および/または治療剤
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
KR20250099259A (ko) * 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN110869053A (zh) * 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
TW202102221A (zh) 2021-01-16
AU2025256180A1 (en) 2025-11-13
JP2022524576A (ja) 2022-05-09
US20230027066A1 (en) 2023-01-26
KR20260049872A (ko) 2026-04-14
BR112021017198A2 (pt) 2021-11-16
EP3941473A1 (en) 2022-01-26
EP4763281A2 (en) 2026-06-24
WO2020188505A1 (en) 2020-09-24
IL285910A (en) 2021-10-31
AU2020243514A1 (en) 2021-08-26
SG11202108810YA (en) 2021-10-28
CA3129024A1 (en) 2020-09-24
PH12021551975A1 (en) 2022-07-04
CN121489955A (zh) 2026-02-10
CN113840607A (zh) 2021-12-24
KR20210142004A (ko) 2021-11-23
TW202506129A (zh) 2025-02-16
JP2025084777A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2022000143A (es) Metodos novedosos.
MX2020008086A (es) Metodos y composiciones para tratar la apnea del sue?o.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
AR119158A1 (es) Tratamientos de angioedema hereditario
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
CO2024003723A2 (es) Compuestos de imidazopiridazina inhibidores de il-17
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
UY39957A (es) Compuestos de imidazopiridazina inhibidores de il-17
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
CL2021001397A1 (es) Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CO2020001887A2 (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático
CO2023004447A2 (es) Composiciones y métodos para el tratamiento de distrofias musculares
CL2022002317A1 (es) Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.